Increasing Resistance of Nosocomial and Community-Acquired Escherichia coli in Clinical Samples from Hospitals and Clinics in Sana’a City

• DOI: 10.22207/jpam.18.3.23
• Publication Date: 2024-08-05T15:07:13Z
• Authors: Talal Alharazi; Mohammed A. Alhoot; Tawfique K. Alzub...; Abdu Aldarhami; Abdulrahman S Bazaid; Husam Qanash; Jerold C. Alcantara; Hattan S. Gattan; Hafez Alsumairy
• Keywords: Nitrofurantoin; MacConkey agar; Tazobactam

Antimicrobial resistance in Escherichia coli presents a global challenge associated with nosocomial infections and increased mortality rates. Understanding profiles is crucial for guiding treatment strategies ensuring effective antibiotic use. This study aimed to investigate the prevalence vitro of E. community-acquired infections. Various clinical samples from 700 patients were cultured on MacConkey’s medium blood agar. The disk diffusion method was used determine susceptibility profile isolates following guidelines Clinical Laboratory Standards Institute (CLSI). Urine, pus, seminal fluid, vaginal swabs, other body fluids among analyzed. Of 112 isolates, 48.2% inpatients 51.8% outpatients, majority (66%) isolated urine samples. Higher levels observed urinary than that previously recorded data same institutions. Notably, exhibited high penicillin (98.2%), ampicillin (97.3%), first-generation cephalosporins (90.2%), erythromycin (72.2%), roxithromycin (95.4%), whereas lower noted against piperacillin-tazobactam (25.0%), nitrofurantoin (12.5%), imipenem (9.8%). overall multidrug rate 62.5%, higher rates (70%) compared (55.6%). However, this difference not statistically significant (p>0.05). underscores (27.0%) highlights concerning level resistance, particularly older antibiotics. These findings emphasize importance judicious use ongoing surveillance.